, Cancer of the Pancreas-Cancer Stat Facts, 2017.
Appareil digestif-Cancer du pancréasMaladie-Epidémiologie, 2017. ,
Rising incidence of pancreatic cancer in France, Pancreas, vol.39, issue.8, pp.1243-1249, 2010. ,
Pancreatic cancer. The Lancet, vol.388, pp.73-85, 2016. ,
Hereditary pancreatic cancer: related syndromes and clinical perspective. Hered Cancer Clin Pract, vol.15, p.9, 2017. ,
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, N Engl J Med, vol.350, issue.12, pp.1200-1210, 2004. ,
,
, Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection: A Randomized Controlled Trial, JAMA, vol.304, issue.10, pp.1073-81, 2010.
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. The Lancet, vol.389, pp.1011-1035, 2017. ,
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for 61 patients with advanced pancreas cancer: a randomized trial, J Clin Oncol, vol.15, issue.6, pp.2403-2416, 1997. ,
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol Off J Am Soc Clin Oncol, vol.25, issue.15, pp.1960-1966, 2007. ,
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N Engl J Med, vol.369, issue.18, pp.1691-703, 2013. ,
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients, BMJ, vol.3, issue.7456, pp.15-24, 2004. ,
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort, Ann Surg Oncol, vol.22, issue.1, pp.295-301, 2015. ,
Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity-Ready for clinical practice?, Cancer Treat Rev, vol.50, pp.23-34, 2016. ,
PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.32, issue.21, pp.2240-2247, 2014. ,
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial, Lancet Lond Engl, vol.376, issue.9742, pp.687-97, 2010. ,
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial, JAMA Oncol, vol.3, issue.4, pp.516-538, 2017. ,
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation, J Clin Oncol Off J Am Soc Clin Oncol, vol.33, issue.3, pp.244-50, 2015. ,
Médecine personnalisée en cancérologie digestive Vers un traitement à la carte, 2013. ,
Cancer colorectal et sujets âgés : y a-t-il une spécificité de prise en charge ?, 2016. ,
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study, J Clin Oncol, vol.29, issue.25, p.3457, 2011. ,
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment, Clin Cancer Res Off J Am Assoc Cancer Res, vol.15, issue.8, pp.2920-2926, 2009. ,
Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.24, pp.4495-502, 2016. ,
Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy, Br J Cancer, vol.88, issue.2, pp.181-187, 2003. ,
Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy, Cancer Chemother Pharmacol, vol.68, issue.5, pp.1305-1318, 2011. ,
Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients, Cancer Res, vol.52, issue.10, pp.2899-902, 1992. ,
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5fluorouracil, Eur J Cancer, vol.40, issue.7, pp.939-50, 2004. ,
DPD deficiency in patients treated with fluorouracil, Lancet Oncol, vol.16, issue.16, pp.1574-1580, 2015. ,
Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer, Br J Clin Pharmacol, vol.81, issue.1, pp.124-154, 2016. ,
Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs, Expert Opin Drug Metab Toxicol, vol.11, issue.5, pp.665-72, 2015. ,
Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen, Pharmacogenomics, vol.14, issue.9, pp.1047-51, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01708020
Pharmacogenomics Knowledge for Personalized Medicine, Clin Pharmacol Ther, 2012. ,
5-fluorouracile : données sur le métabolisme et place actuelle dans le traitement des cancers digestifs ,
, Fluoropyrimidine Pathway, Pharmacodynamics [Internet]. PharmGKB, 2017.
, Fluoropyrimidine Pathway, Pharmacokinetics, 2009.
Translational reprogramming of colorectal cancer cells induced by 5-fluorouracil through a miRNAdependent mechanism, Oncotarget, vol.8, issue.28, pp.46219-46252, 2017. ,
, Medical Genetics Summaries
, National Center for Biotechnology Information (US
, Antimetabolite Pathway-Folate Cycle, Pharmacodynamics [Internet]. PharmGKB, p.2017
, , 2009.
, Les alkylants doubles brins, 2017.
Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy, Cancer Chemother Pharmacol, vol.77, issue.1, pp.5-18, 2016. ,
Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting ,
, Clin Pharmacol Ther, vol.99, issue.2, pp.172-85, 2016.
UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice, Fundam Clin Pharmacol. 2015 juin, vol.29, issue.3, pp.219-256 ,
Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform, Pharmacogenomics, 2010. ,
Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study, BMC Cancer, vol.16, issue.1, p.823, 2016. ,
Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer, Clin Cancer Res Off J Am Assoc Cancer Res, vol.15, issue.22, pp.6973-6982, 2009. ,
, Annotation of CPIC Guideline for fluorouracil and DPYD [Internet]. PharmGKB, p.2017
, Annotation of PRO Guideline for irinotecan and UGT1A1, p.2017
Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy, Gene, vol.559, issue.1, pp.31-38, 2015. ,
SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours, Br J Cancer, vol.110, issue.2, pp.304-316, 2014. ,
Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?, J Clin Pharmacol, vol.56, pp.40-58, 2016. ,
SLCO1B1 and SLC19A1 Gene Variants and Irinotecan-Induced Rapid Response and Survival: A Prospective Multicenter Pharmacogenetics Study of Metastatic Colorectal Cancer, PLOS ONE, vol.8, issue.10, p.77223, 2013. ,
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study ,
, Pharmacogenomics J, vol.16, issue.1, pp.54-63, 2016.
Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients, Pharmacogenet Genomics, vol.22, issue.9, pp.659-66, 2012. ,
The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia, Pharmacogenomics J, vol.14, issue.4, pp.328-363, 2014. ,
URL : https://hal.archives-ouvertes.fr/in2p3-00373791
, Genes and Immunity-Sequence variation, linkage disequilibrium and association with Crohn's disease on chromosome 5q31, 2017.
A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients. Sci Rep, vol.7, p.7059, 2017. ,
CYP1B1 gene polymorphism modifies pancreatic cancer risk but not survival, Neoplasma, vol.57, issue.1, pp.15-24, 2010. ,
Estrogen Metabolism, and Cancer Risk ,
, , 2016.
C4ST-1/CHST11-controlled chondroitin sulfation interferes with oncogenic HRAS signaling in Costello syndrome, Eur J Hum Genet, vol.20, issue.8, pp.870-877, 2012. ,
Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms, Oncol Rep, vol.27, issue.2, pp.409-424, 2012. ,